Our findings suggest that in a subset of severe sepsis patients driven by endotoxemia, early targeting of IL-1β may represent a rational therapeutic strategy to slow endotoxin release and attenuate sepsis progression, potentially reducing the severity of the cytokine storm and associated mortality, albeit at the cost of a prolonged recovery period. The gene discussed is IL1B; the disease is serum lipopolysaccharide activity.